Treatment with AD brain tau resulted in 96 significant (p < 0.05) differentially expressed genes (DEGs), while treatment with equivalent control brain fractions showed 68 DEGs, of which 31 genes were common to both AD and control treated astrocytes (Figures 5A and 5B). The gene discussed is MAPT; the disease is Alzheimer disease.